Peng Gui-Qin, Song Hai-Chi, Chen Wan-Yi
Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing 400030, China.
World J Clin Oncol. 2024 Jul 24;15(7):945-952. doi: 10.5306/wjco.v15.i7.945.
Epidermal growth factor receptor () mutation and c-ros oncogene 1 () rearrangement are key genetic alterations and predictive tumor markers for non-small cell lung cancer (NSCLC) and are typically considered to be mutually exclusive. co-mutation is a rare event, and the standard treatment approach for such cases is still equivocal.
Herein, we report the case of a 64-year-old woman diagnosed with lung adenocarcinoma, with concomitant L858R mutation and rearrangement. The patient received two cycles of chemotherapy after surgery, but the disease progressed. Following 1-month treatment with gefitinib, the disease progressed again. However, after switching to crizotinib, the lesion became stable. Currently, crizotinib has been administered for over 53 months with a remarkable treatment effect.
The efficacy of tyrosine kinase inhibitors and crizotinib was vastly different in this NSCLC patient with / co-mutation. This report will aid future treatment of such patients.
表皮生长因子受体（EGFR）突变和原癌基因酪氨酸蛋白激酶（ROS1）重排是非小细胞肺癌（NSCLC）的关键基因改变和预测性肿瘤标志物，通常被认为是相互排斥的。EGFR/ROS1共突变是一种罕见事件，此类病例的标准治疗方法仍不明确。
在此，我们报告一例64岁女性，诊断为肺腺癌，伴有EGFR L858R突变和ROS1重排。患者术后接受了两个周期的化疗，但疾病进展。在接受吉非替尼治疗1个月后，疾病再次进展。然而，换用克唑替尼后，病灶变得稳定。目前，克唑替尼已给药超过53个月，治疗效果显著。
在这位伴有EGFR/ROS1共突变的NSCLC患者中，EGFR酪氨酸激酶抑制剂和克唑替尼的疗效差异很大。本报告将有助于未来对此类患者的治疗。
